Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Unicycive securities between December 29, 2025, and June 29, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case.
Unicycive Case Details
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that:
- Unicycive had not inspected its third-party manufacturing vendor’s facility or otherwise audited the facility’s compliance with current good manufacturing practices;
- consequently, Unicycive lacked a reasonable basis to believe that the vendor had remedied the deficiencies cited by the FDA;
- there was a material undisclosed risk that the FDA would require additional information concerning the vendor’s manufacturing practices;
- as a result, regulatory approval of oxylanthanum carbonate was reasonably likely to be delayed; and
- accordingly, Defendants’ positive statements concerning Unicycive’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.
What’s Next for Unicycive Investors?
A class action lawsuit has already been filed. You may review a copy of the Complaint. You may also contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911. If you suffered a loss in Unicycive you have until November 2, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff.
UNCY — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”